Effect of buspirone on sexual dysfunction in depressed patients treated with selective serotonin reuptake inhibitors

Journal of Clinical Psychopharmacology

Volumn 19, Issue 3, 1999, Pages 268-271

  Landén, Mikael ^a,b   Eriksson, Elias ^a   Ågren, Hans ^a   Fahlén, Tom ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BUSPIRONE; CITALOPRAM; PAROXETINE; SEROTONIN UPTAKE INHIBITOR;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG EFFECT; EJACULATION; FEMALE; HUMAN; LIBIDO; MAJOR CLINICAL STUDY; MALE; ORGASM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; SEXUAL DYSFUNCTION; TREATMENT OUTCOME;

ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BUSPIRONE; CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; PAROXETINE; SEROTONIN UPTAKE INHIBITORS; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL;

EID: 0032925471     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199906000-00012     Document Type: Article

References (28)

1. Stein DJ, Hollander E. Sexual dysfunction associated with the drug treatment of psychiatric disorders. CNS Drugs 1994;2: 78-86.
2. Segraves RT. Psychopharmacological influences on human sexual behavior. In: Oldham JM, Riba MB, ed. American Psychiatric Press review of psychiatry, vol. 14. Washington, DC: American Psychiatric Press, 1995:697-718.
3. Monteiro WO, Noshirvani HF, Marks IM, Lelliot PT. Anorgasmia from clomipramine in obsessive-compulsive disorder: a controlled trial. Br J Psychiatry 1987;151:107-12.
4. Eriksson E, Hedberg MA, Andersch B, Sundblad C. The serotonin reuptake inhibitor paroxetine is superior to the noradrenaline reuptake inhibitor maprotiline in the treatment of premenstrual syndrome. Neuropsychopharmacology 1995;12:167-76.
5. Shen WW, Hsu JH. Female sexual side effects associated with selective serotonin reuptake inhibitors: a descriptive clinical study of 33 patients. Int J Psychiatry Med 1995;25:239-48.
6. Feiger A, Kiev A, Shrivastava RK, Wisselink PG, Wilcox CS. Nefazodone versus sertraline in outpatients with major depression: focus on efficacy, tolerability, and effects on sexual function and satisfaction. J Clin Psychiatry 1996;57[suppl 2]:53-62.
7. Herman JB, Brotman AW, Pollack MH, Falk WE, Biederman J, Rosenbaum JF. Fluoxetine-induced sexual dysfunction. J Clin Psychiatry 1990;51:25-7.
8. Zajecka J, Fawcett J, Schaff M, Jeffriess H, Guy C. The role of serotonin in sexual dysfunction: fluoxetine-associated orgasm dysfunction. J Clin Psychiatry 1991;52:66-8.
9. Balon R. Fluoxetine and sexual dysfunction [letter]. JAMA 1995; 273:1489.
10. Sundblad C, Wikander I, Andersch B, Eriksson E. A naturalistic study of paroxetine in premenstrual syndrome: efficacy and side effects during ten cycles of treatment. Eur Neuropsychopharmacol 1997;7:201-6.
11. Waldinger MD, Hengeveld MW, Zwinderman AH. Paroxetine treatment of premature ejaculation: a double-blind, randomized, placebo-controlled study. Am J Psychiatry 1994;151:1377-9.
12. Kara H, Aydin S, Yucel M, Agargun MY, Odabas O, Yilmaz Y. The efficacy of fluoxetine in the treatment of premature ejaculation: a double-blind placebo controlled study [see comments]. J Urol 1996;156:1631-2.
13. Othmer E, Othmer SC. Effect of buspirone on sexual dysfunction in patients with generalized anxiety disorder. J Clin Psychiatry 1987;48:201-3.
14. Norden MJ. Buspirone treatment of sexual dysfunction associated with selective serotonin re-uptake inhibitors. Depression 1994;2:109-12.
15. Landén M, Bjorling G, Agren H, Fahlén T. A randomized, double-blind, placebo-controlled trial of buspirone in combination with an SSRI in patients with treatment-refractory depression. J Clin Psychiatry 1998;59:664-8.
16. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale: a new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 1987;334: 1-100.
17. Guy W. ECDEU assessment manual for psychopharmacology 534-7. Washington, DC: U.S. Department of Health, Education and Welfare, 1976.
18. Tallentire D, McRae G, Spedding M, Clark R, Vickery B. Modulation of sexual behaviour in the rat by a potent and selective alpha 2-adrenoceptor antagonist, delequamine (RS-15385-197). Br J Pharmacol 1996;118:63-72.
19. Hollander E, McCarley A. Yohimbine treatment of sexual side effects induced by serotonin reuptake blockers. J Clin Psychiatry 1992;53:207-9.
20. Jacobsen FM. Fluoxetine-induced sexual dysfunction and an open trial of yohimbine. J Clin Psychiatry 1992;53:119-22.
21. 2 antagonist, in the treatment of sexual dysfunction induced by serotonin reuptake inhibitors. Clin Neuropharmacol 1997;20:210-4.
22. Blier P, Curet O, Chaput Y, De Montigny C. Tandospirone and its metabolite, 1-(2-pyrimidinyl)piperazine: II. Effects of acute administration of 1-PP and long-term administration of tandospirone on noradrenergic neurotransmission. Neuropharmacology 1991;30:692-702.
23. Ahlenius S, Larsson K, Arvidsson LE. Effects of stereoselective 5-HT-1A agonists on male rat sexual behavior. Pharmacol Biochem Behav 1989;33:691-5.
24. Eison AS, Temple DL Jr. Buspirone review of its pharmacology and current perspectives on its mechanism of action. Am J Med 1986;80:1-9.
25. Balogh S, Hendricks SE, Kang J. Treatment of fluoxetine-induced anorgasmia with amantadine [letter]. J Clin Psychiatry 1992;53: 212-3.
26. Elmore JL, Quattlebaum JT. Female sexual stimulation during antidepressant treatment. Pharmacotherapy 1997;17:612-6.
27. Bartlik BD, Kaplan P, Kaplan HS. Psychostimulants apparently reverse sexual dysfunction secondary to selective serotonin reuptake inhibitors. J Sex Marital Ther 1995;21:264-71.
28. Modell JG, Katholi CR, Modell JD, DePalma RL. Comparative sexual side effects of bupropion, fluoxetine, paroxetine, and sertraline. Clin Pharmacol Ther 1997;61:476-87.